Elotuzumab plus len-dex extends remissions of multiple myelomaMay 13, 2015Leukemia, Myelodysplasia, Transplantation
Inotuzumab ozogamicin study reaches primary endpoint for ALLApril 28, 2015Leukemia, Myelodysplasia, Transplantation
Encouraging outcomes continue following CAR T cell therapy in kidsApril 24, 2015Leukemia, Myelodysplasia, Transplantation
New drugs signal promise for rare leukemia, prostate cancerApril 2, 2015Genitourinary CancerLeukemia, Myelodysplasia, TransplantationRare Diseases
Long-term endocrine effects common after reduced-intensity chemotherapy in childrenMarch 26, 2015PediatricsLeukemia, Myelodysplasia, TransplantationPatient & Survivor Care
Similar outcomes from HSCT found with sibling and unrelated donorsMarch 9, 2015Leukemia, Myelodysplasia, TransplantationRare Diseases
Anti-CD38 antibodies poised to transform myeloma treatmentJanuary 5, 2015Leukemia, Myelodysplasia, TransplantationRare Diseases
Sorafenib boosts event-free survival of adult AMLDecember 8, 2014Leukemia, Myelodysplasia, Transplantation
Young adults with ALL have better survival with pediatric regimensDecember 8, 2014Leukemia, Myelodysplasia, Transplantation
ASPIRE: Carfilzomib-Len-Dex ‘a new standard of care’ for relapsed multiple myelomaDecember 7, 2014Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
FDA expands ruxolitinib approval to include polycythemia veraDecember 4, 2014Leukemia, Myelodysplasia, Transplantation
FDA approves blinatumomab for Philadelphia-negative ALLDecember 3, 2014Leukemia, Myelodysplasia, Transplantation
ASH 2014 to highlight novel cancer therapies, longer follow-up resultsDecember 3, 2014Leukemia, Myelodysplasia, Transplantation
FDA panel votes against panobinostat as add-on therapy for multiple myelomaNovember 7, 2014Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
